Lubiprostone for constipation and irritable bowel syndrome with constipation

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 6, 2008, Pages 727-733

  Tuteja, Ashok K ^a   Rao, Satish S C ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Chloride channels; Constipation; Irritable bowel syndrome; Lubiprostone

Indexed keywords

CHLORIDE CHANNEL; DOCUSATE CALCIUM; DOCUSATE SODIUM; LACTULOSE; LAXATIVE; LUBIPROSTONE; MACROGOL 3350; PLACEBO; TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DERIVATIVE; PROSTAGLANDIN E1;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALLERGIC REACTION; ARTICLE; CHRONIC IDIOPATHIC CONSTIPATION; CLINICAL TRIAL; CONSTIPATION; DEFECATION HABIT; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FETUS RISK; FLUID INTAKE; FOOD DRUG INTERACTION; HEALTH FOOD; HUMAN; INTESTINE MUCOSA PERMEABILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; LACTATION; LIVER TOXICITY; NAUSEA; NONHUMAN; PREGNANCY; QUALITY OF LIFE; STOMACH EMPTYING; CHEMISTRY; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; FOOD AND DRUG ADMINISTRATION; MALE; PATHOPHYSIOLOGY; UNITED STATES;

ALPROSTADIL; CHLORIDE CHANNELS; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 61549122055     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.6.727     Document Type: Article

References (50)

1. Drossman DA, Li Z, Andruzzi E et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Dis. Sci. 38, 1569-1580 (1993).
2. Everhart JE, Go VL, Johannes RS et al. A longitudinal survey of self-reported bowel habits in the United States. Dig. Dis. Sci. 34, 1153-1162 (1989).
3. Pare P, Ferrazzi S, Thompson WG et al. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am. J. Gastroenterol. 96, 3130-3137 (2001).
4. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 130, 1480-1491 (2006).
5. Lau EM, Chan FK, Ziea ET et al. Epidemiology of irritable bowel syndrome in Chinese. Dig. Dis. Sci. 47, 2621-2624 (2002).
6. Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am. J. Gastroenterol. 97, 1910-1915 (2002).
7. Brandt LJ, Prather CM, Quigley EM et al. Systematic review on the management of chronic constipation in North America. Am. J. Gastroenterol. 100 (Suppl. 1), S5-S21 (2005).
8. Longstreth G, Thompson WG, Chey WD et al. Functional bowel disorders. In: Rome III: The Functional Gastrointestinal Disorders (1st Edition). Drossman DA, Corazziari E, Delvaux M et al. (Eds). Degnon Associates, McLean, VA, USA (2006).
9. Lembo A, Camilleri M. Chronic constipation. N. Engl. J. Med. 349, 1360-1368 (2003).
10. Rao SS, Tuteja AK, Vellema T et al. Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J. Clin. Gastroenterol. 38, 680-685 (2004).
11. Rao SS. Dyssynergic defecation. Gastroenterol. Clin. North Am. 30, 97-114 (2001).
12. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment. Pharmacol. Ther. 25, 599-608 (2007).
13. Bosshard W, Dreher R, Schnegg JF et al. The treatment of chronic constipation in elderly people: an update. Drugs Aging 21, 911-930 (2004).
14. Tuteja AK, Talley NJ, Joos SK et al. Is constipation associated with decreased physical activity in normally active subjects? Am. J. Gastroenterol. 100, 124-129 (2005).
15. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am. J. Gastroenterol. 100, 936-971 (2005).
16. Jones MP, Talley NJ, Nuyts G et al. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig. Dis. Sci. 47, 2222-2230 (2002).
17. Tramonte SM, Brand MB, Mulrow CD et al. The treatment of chronic constipation in adults. A systematic review. J. Gen. Intern. Med. 12, 15-24 (1997).
18. Chapman RW, Sillery J, Fontana DD et al. Effect of oral dioctyl sodium sulfosuccinate on intake-output studies of human small and large intestine. Gastroenterology 89, 489-493 (1985).
19. Fain AM, Susat R, Herring M et al. Treatment of constipation in geriatric and chronically ill patients: a comparison. South. Med. J. 71, 677-680 (1978).
20. Xing JH, Soffer EE. Adverse effects of laxatives. Dis. Colon Rectum 44, 1201-1209 (2001).
21. Schiller LR. Review article: the therapy of constipation. Aliment. Pharmacol. Ther. 15, 749-763 (2001).
22. Bass P, Dennis S. The laxative effects of lactulose in normal and constipated subjects. J. Clin. Gastroenterol. 3 (Suppl. 1), 23-28 (1981).
23. Candelli M, Nista EC, Zocco MA et al. Idiopathic chronic constipation: pathophysiology, diagnosis and treatment. Hepatogastroenterology 48, 1050-1057 (2001).
24. Voskuijl W, de Lorijn F, Verwijs W et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut 53, 1590-1594 (2004).
25. Dipalma JA, Cleveland MV, McGowan J et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am. J. Gastroenterol. 102, 1436-1441 (2007).
26. Exton-Smith AN, Bendall MJ, Kent F. A new technique for measuring the consistency of faeces: a report on its application to the assessment of Senokotot therapy in the elderly. Age Ageing 4, 58-62 (1975).
27. Marlett JA, Li BU, Patrow CJ et al. Comparative taxation of psyllium with and without senna in an ambulatory constipated population. Am. J. Gastroenterol. 82, 333-337 (1987).
28. Singh G, Lingala V, Wang H et al. Use of health care resources and cost of care for adults with constipation. Clin. Gastroenterol. Hepatol. 5, 1053-1058 (2007).
29. Bao HF, Liu L, Self J et al. A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G234-G251 (2008).
30. Cuppoletti J, Malinowska DH, Tewari KP et al. SPI-0211 activates T84 cell chloride transport and recombinant human C1C-2 chloride currents. Am. J. Physiol. Cell Physiol. 287, C1173-C1183 (2004).
31. Jentsch TJ, Stein V, Weinreich F et al. Molecular structure and physiological function of chloride channels. Physiol. Rev. 82, 503-568 (2002).
32. Lipecka J, Bali M, Thomas A et al. Distribution of C1C-2 chloride channel in rat and human epithelial tissues. Am. J. Physiol. Cell Physiol. 282, C805-C816 (2002).
33. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol. Rev. 79, S23-S45 (1999).
34. Camilleri M, Bharucha AE, Ueno R et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G942-G947 (2006).
35. Jentsch TJ. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit. Rev. Biochem. Mol. Biol. 43, 3-36 (2008).
36. Mohammad-Panah R, Ackerley C, Rommens J et al. The chloride channel C1C-4 co-localizes with cystic fibrosis transmembrane conductance regulator and may mediate chloride flux across the apical membrane of intestinal epithelia. J. Biol. Chem. 177, 566-574 (2002).
37. Amitiza™, package insert. Sucampo Pharmaceuticals Inc. & Takeda Pharmaceuticals Inc, IL, USA.
38. Ueno R, Osama H, Habe T et al. Oral SPI-0211 increases fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterology 126(Suppl. 2), A-298 (Abstract M1109) (2004).
39. Moeser AJ, Nighot PK, Engelke KJ et al. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the C1C-2 chloride channel, lubiprostone. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G647-G656 (2007).
40. Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol. Motil. 19, 545-552 (2007).
41. Cuppoletti J, Malinowska DH, Chakrabarti J et al. Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat. 86, 56-60 (2008).
42. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment. Pharmacol. Ther. 25, 1351-1361 (2007).
43. Johanson JF, Morton D, Geenen J et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am. J. Gastroenterol. 103, 170-177 (2008).
44. Ueno R, Wahle A, Panas R et al. Evaluation of safety and efficacy in a 12-month study of lubiprostone for the treatment of chronic idiopathic constipation. Am. J. Gastroenterol., (Abstract 1112) 2006.
45. Johanson JF, Drossman DA, Panas R et al. Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 27, 685-696 (2008).
46. Thompson WG, Longstreth G, Drossman DA, Heaton K, Irvine EJ, Muller-Lissner S. Functional bowel disorders and functional abdominal pain. In: The Functional Gastrointestinal Disorders (2nd Edition). Drossman DA, Corazziari E, Talley NJ et al (Eds). Degnon Associates, McLean, VA, USA (2000).
47. Drossman D, Chey W, Panas R, Wahle A, Scott C, Ueno R. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two twelve-week, randomized, placebo-controlled, double-blind trials. Gastroenterology 132, 2586-2587 (Abstract 639G) (2007).
48. Patrick DL, Drossman DA, Frederick IO et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig. Dis. Sci. 43, 400-411 (1998).
49. Drossman D, Chey WD, Scott C et al. Health-related quality of life in adults with irritable bowel syndrome and constipation: results of a combined analysis of two Phase 3 studies with lubiprostone. Gastroenterology 4 (Suppl. 1), A469 (Abstract T1036) (2008).
50. Chey WD, Drossman D, Scott C et al. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. Gastroenterology 4(Suppl. 1), A215 (2008) (Abstract S1272).